AstraZeneca Plc reported better-than-expected third-quarter product sales on Thursday, on the back of strong demand for newer medicines including cancer treatments Tagrisso and Lynparza as well as growth in China. Product sales for the three months ended Sept. 30 rose 18% to $6.13 billion on a constant-currency basis, the company's fifth consecutive quarter of growth after years of sliding sales due to patent losses on older medicines.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!